
Allogene Therapeutics describes what it is doing as "The next revolution in cell therapy." In more detail they describe themselves as "a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer."
Below are quotes from a recent market report describing a sharp jump in the Allogene share price.
Further reading
More >
Investment Alerts
Barclays Walks a Stock Chart Tightrope
March 24, 2023

Investment Alerts
Pros and Cons of Big Picture Share Trading Indicators
March 23, 2023

Investment Alerts
Bitcoin at $1 Million – Why Not?
March 22, 2023

Investment Alerts
Artificial Intelligence Revolution: 3 Companies That Will Benefit
March 21, 2023